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harbored HER2 amplifications and 
HER2 mutations, respectively. These 
results are mostly consistent with those 
of Yoshimasu et al.
Importantly, our study data also 
suggested that the sensitivity to cisplatin 
depended not only on EGFR mutations 
but also on other driver mutations the 
tumor harbored and on the epithelial- 
mesenchymal transition phenotype. 
For example, the EGFR mutant H1975, 
with some features of EMT,5 was 
relatively sensitive to cisplatin. Five 
cell lines with MET amplifications 
or HER2 abnormalities, all with high 
levels of E-cadherin mRNA, showed 
IC50 values similar to those of EGFR 
mutants. It was also of interest that 
KRAS-mutated cells with low levels 
of E-cadherin mRNA were more sensi-
tive to cisplatin, while KRAS-mutated 
cells with high levels of E-cadherin 
mRNA were highly resistant to cis-
platin (Figure 1). We did not find any 
correlations between ERCC1 and beta 
III tubulin expressions and sensitivities 
to cisplatin and paclitaxel, respectively 
(data not shown).
In light of our results, it would 
be more informative to analyze genetic 
abnormalities other than EGFR, as well 
as histologic features and E-cadherin 
expression, in the study by Yoshimasu 
et al. We would like to stress that EGFR 
wild-type tumors are actually hetero-
geneous tumors with regard to driver 
mutations, such as the KRAS mutation, 
HER2 mutation, ALK rearrangement, 
etc., and the EMT phenotype, and the 
proportion of these heterogeneous 
tumors may differ in different ethnic 
groups. Therefore, the results compar-
ing the EGFR-mutant and EGFR wild-
type tumors must be interpreted with 
caution.
In summary, we appreciate the 
work by Yoshimasu et al. regarding 
EGFR mutations and chemosensitivi-
ties, but we believe that genetic pro-
files other than the EGFR mutation 
and EMT phenotype need to be con-
sidered when analyzing sensitivities 
to chemotherapeutic agents, especially 
cisplatin.
Daisuke Matsubara, PhD, MD
Toshiro Niki, PhD, MD
Department of Pathology
Jichi Medical University
Shimotsuke, Tochigi, Japan
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In Response:
We thank Dr. Matsubara and 
coworkers for their interest in our article 
and presenting their informative data. It 
is known that epidermal growth factor 
receptor (EGFR) mutation-positive and 
-negative tumors have different char-
acteristics. Therefore, we consider that 
chemosensitivity profiles for anticancer 
agents are not identical between EGFR 
mutation-positive and -negative tumors.
As Dr. Matsubara mentioned in his 
letter, EGFR mutation-negative tumors 
are heterogenous. Tumors with various 
driver mutations are included in this 
group. We also agree that tumors with 
different driver mutations have the pos-
sibility of showing different chemosensi-
tivity profiles. Their data clearly provide 
evidence for this issue.1
It is also important to be aware 
that these genetic alterations probably 
do not directly regulate chemosensitivity 
for anticancer agents, unlike ERCC1 and 
class-III β-tubulin.2,3 We surmise that the 
EGFR gene does not directly regulate 
chemosensitivity for docetaxel. our data, 
as well as Dr. Matsubara’s data, may only 
show that different cancers have differ-
ent chemosensitivity profiles.
The prognosis of patients with 
advanced non–small-cell lung cancer 
(NSCLC) highly depends on their EGFR 
mutation status. Therefore, the EGFR 
mutation status is now routinely tested in 
patients with NSCLC in clinical practice. 
This can be useful if the EGFR mutation 
status also provides some more informa-
tion regarding chemosensitivity for cyto-
toxic anticancer agents. our article has 
provided such data.
To investigate predictive markers 
for cancer chemotherapy, established 
cell lines are useful and powerful 
tools. However, this involves some 
limitations. Cell lines cannot be estab-
lished from all lung-cancer specimens. 
Usually they originate from a highly 
malignant subgroup, and then they 
involve a certain selection bias.4 our 
approach, based on the histoculture 
drug response assay, is a solution to 
reduce this selection bias.
It is unknown whether some driver 
mutations in NSCLC directly regulate 
chemotherapy responses. our histocul-
ture drug response assay–based approach 
does not seem to be suitable for investi-
gating this problem. Further investigation 
by Dr. Matsubara’s research group using 
an established cell-line panel might be 
helpful.
Tatsuya Yoshimasu, MD, PhD
Department of Thoracic and 
Cardiovascular Surgery 
Wakayama Medical University
Wakayama, Japan
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KRAS Mutation 
Spectrum Notably 
Diverges between 
Non-small Cell 
Lung and Colorectal 
Carcinomas
To the Editor:
We read the article entitled “A sys-
tematic review and Canadian consensus 
recommendations on the use of biomark-
ers in the treatment of non-small cell 
lung cancer” by Ellis et al.1 with major 
interest and would like to address com-
ment on it. Since 2008, clinical research 
studies on non-small cell lung cancer 
(NSCLC) have allowed the transfer of 
EGFR gene mutations testing to the rou-
tine analysis for predicting the response 
to tyrosine kinase inhibitors (TKI) such 
as gefitinib or erlotinib. Therefore, inter-
est in individualizing patient treatment 
to maximize clinical benefit has become 
a focus of scientific investigation. The 
presence of a translocation involving the 
anaplastic lymphoma kinase (ALK) gene 
with EML4 is now admitted to confer 
a remarkable sensitivity to crizotinib, a 
specific ALK TKI. In contrast, mutations 
activating the KRAS oncogene are gener-
ally reported as associated with a lack of 
response to EGFR TKI in several studies, 
but the mechanism remains unclear and 
controversial thus insufficient to adopt 
KRAS mutation detection as a consen-
sual tool for therapeutic decision.2–5
When entering into details of 
KRAS somatic mutations, their predic-
tive value in stage IV colorectal cancer 
(CRC) patients for treatment with EGFR 
monoclonal antibodies has been estab-
lished. RAS mutations are found in 40 
to 45% of metastatic colorectal adeno-
carcinomas, and the mutation spectrum 
has been extensively studied, mutations 
involving codon 12 or 13 of KRAS being 
found in 40% of cases and the remain-
ing 5% being spread over KRAS codons 
61 and 146 or NRAS. on KRAS codons 
12 and 13, seven mutations have been 
recognized as the most frequent, leading 
to the development of commercial kits 
focusing on these seven mutations. The 
use of these kits has been extended to 
other tumor types, in particular NSCLC, 
as able to predict the absence of EGFR 
mutation or ALK translocation as these 
events have been reported as mutually 
exclusive, instead of predicting a specific 
resistance to EGFR TKI. Also, the strat-
egy of drug development moves toward 
the ability of specifically targeting the 
RAS pathway.
Involved in somatic mutations 
detection in our Cancer Institute, we 
evaluated the possibility to use those kits 
targeted on the seven most frequent KRAS 
mutations that are less expensive and time 
consuming when compared with nonse-
lective techniques like sequencing. From 
June 2006 to September 2011, a consec-
utive series of 1642 histologic samples 
of metastatic CRC patients has been 
referred to the bio-pathologic depart-
ment for sequencing the KRAS codons 
12 and 13 mutation status before enroll-
ing patients in cetuximab-based proto-
cols, and 633 mutations were recorded 
(39%). Since January 2009, an additional 
762 samples from patients affected by 
NSCLC was screened using the same 
approach, leading to the identification 
of 186 mutations (24.4%) (Table 1). 
When comparing the mutation spectra of 
these two tumor types, no major differ-
ence in frequencies is observed except 
for c.37G>T and for delins mutations 
that are found in 15 of CRC, i.e., 2.3% 
of mutated samples, and 27 of NSCLC, 
i.e., 14.5% of mutated samples. These 
mutations are not precisely or unreliably 
detected using the commercial kits. If the 
proportion of missed mutations is quite 
low in CRC, it is much higher in NSCLC 
and cannot be neglected. In those cases, 
there is a risk to treat with an ineffective 
therapy, and in the future these patients 
could lack chance of having a RAS-
targeted therapy.
In summary, meta-analyses on 
molecular biomarkers usually put 
together results derived from clinical 
studies based on heterogeneous molec-
ular approaches, and subsequent con-
flicting results lead to preclude the use 
of potential markers in medical prac-
tice. When transferring new molecular 
markers in routine testing, we would 
like to recommend a scrupulous con-
sideration when choosing the detection 
technique.
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